Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Array Biopharma (ARRY) Slips to Session Low, Down 4.5%
February 10, 2017 10:43 AM ESTArray Biopharma (NASDAQ: ARRY) Slips to Session Low, Down 4.5%
... MoreArray Biopharma (ARRY) Tops Q2 EPS by 4c
February 9, 2017 8:32 AM ESTArray Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.14), $0.04 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $44.52 million versus the consensus estimate of $30.99 million.
COLUMBUS / BRAF-mutant melanoma New Drug Application (NDA) expected to file in June or July
NEMO /... More
